Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice

Journal of the Pakistan Medical Association

Volumn 64, Issue 10, 2014, Pages 1203-1206

  Dutta, Deep ^a   Kalra, Sanjay ^b  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b India   (India)

Author keywords

Canagliflozin; Cardiovascular safety; Dapagliflozin; Empagliflozin; Genital tract infection; Glycemic efficacy; SGLT2 inhibitors; Side effects

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TRIACYLGLYCEROL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; THIOPHENE DERIVATIVE;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG APPROVAL; DRUG DOSE; DRUG POTENTIATION; GENITAL TRACT INFECTION; GLUCOSURIA; HEMATURIA; HUMAN; HYPOTENSION; INSULIN RESISTANCE; ORTHOSTATIC HYPOTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS;

BENZHYDRYL COMPOUNDS; DIABETES MELLITUS; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84907477364     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-74.
2. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-9.
3. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951; 30: 125-9.
4. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodiumglucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-7.
5. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non-Insulin-Dependent Diabetes. Diabetes 2005; 54: 3427-34.
6. Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92: 158-69.
7. Roden M, Weng J, Eilbracht J, Delafont B4, Kim G5, Woerle HJ, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.? Lancet Diabetes Endocrinol [serial online] 2013 Sep (Cited 2013 Nov 5). Available from URL: http://dx.doi. org/10.1016/S2213-8587(13)70084-6.
8. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013; 15: 1154-60.
9. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-8.
10. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-15.
11. Woerle HJ, Ferrannini E, Berk A, Manun'ebo M, Pinnetti S, Broedl UC. Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes. Diabetes 2012; 61 (Suppl): abstr 49-LB.
12. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose cotransport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014; 8: 330-9.
13. Roumie CL, Liu X, Choma NN, Greevy RA, Hung AM, Grijalva CG, et al. Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year. Pharmacoepidemiol Drug Saf 2012; 21: 515-23.
14. Zhang F, Xiang H, Fan Y, Ganchuluun TA, Kong W, Ouyang Q, et al. The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine. 2013; 44: 648-58.
15. Hettihewa LM, Jayasinghe SS, Imendra KG, Weerarathna TP. Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy. Int J Diabetes Dev Ctries 2008; 28: 26-30.
16. Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013; 27: 280-6.
17. Paisley AN, Yadav R, Younis N, Rao-Balakrishna P, Soran H. Dapagliflozin: a review on efficacy, clinical effectiveness and safety. Expert Opin Investig Drugs 2013; 22: 131-40.
18. Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs 2014; 23: 875-82.
19. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509-14.
20. Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, doubleblind, placebo-controlled study. Diabetes Care 2014; 37: 740-50.
21. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield T, List JA. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebocontrolled 102-week trial. BMC Medicine 2013; 11: 43.
22. Farxiga [package insert], Princeton, NJ; Bristol-Myers Squibb, Inc; 01, 2014.
23. Invokana [package insert], Titusville, NJ; Janssen Pharmaceuticals, Inc; 12, 2013.
24. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013; 9: 529-50.
25. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: Impact of pharmacologicallyinduced glucosuria. Diabetes Res Clin Pract 2014; 103: 373-81.
26. Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 2011; 10: 645-6.
27. Macha S, Mattheus M, Pinnetti S, Seman L, Woerle HJ. Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Glimepiride Following Coadministration in Healthy Volunteers: A Randomised, Open-label, Crossover Study. J Diabetes Res Clini Metabol 2012; 1: 14.